Systemic Therapies for Psoriasis: An Evidence-Based Update
- 5 February 2014
- journal article
- review article
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 15 (3) , 165-180
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Tofacitinib (CP‐690,550), an oral Janus kinase inhibitor, improves patient‐reported outcomes in a phase 2b, randomized, double‐blind, placebo‐controlled study in patients with moderate‐to‐severe psoriasisJournal of the European Academy of Dermatology and Venereology, 2013
- Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled studyHealth and Quality of Life Outcomes, 2013
- Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, dose‐comparison studyJournal of the European Academy of Dermatology and Venereology, 2012
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging studyBritish Journal of Dermatology, 2012
- Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trialThe Lancet, 2012
- Impact of ustekinumab on health‐related quality of life in Japanese patients with moderate‐to‐severe plaque psoriasis: Results from a randomized, double‐blind, placebo‐controlled phase 2 / 3 trialThe Journal of Dermatology, 2012
- Live attenuated varicella vaccine: A new effective adjuvant weapon in the battlefield against severe resistant psoriasis, a pilot randomized controlled trialJournal of the American Academy of Dermatology, 2012
- Consensus Guidelines for the Management of Plaque PsoriasisArchives of Dermatology, 2012
- Efficacy and safety of ustekinumab in Japanese patients with moderate‐to‐severe plaque‐type psoriasis: Long‐term results from a phase 2/3 clinical trialThe Journal of Dermatology, 2011
- Treatment of plaque‐type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trialJournal of the European Academy of Dermatology and Venereology, 2011